文献速递糖尿病

新型胰高血糖素样肽-1受体拮抗抗体的开发与表征

Development and characterisation of a novel glucagon like peptide-1 receptor antibody.
PubMed 文献 · Diabetologia · 2017-11-09

本研究通过噬菌体展示技术筛选出高亲和力单链可变区片段Glp1R0017,并将其转换为人类IgG1抗体。体外实验显示Glp1R0017可拮抗小鼠、人、大鼠、食蟹猴和犬的GLP1R,并减弱GLP-1刺激的cAMP和胰岛素分泌;体内实验表明Glp1R0017可逆转利拉鲁肽的降糖作用并降低糖耐量。该抗体有望用于研究GLP1R在胰腺外组织中的生理作用。

要点

  • Glp1R0017是一种特异性拮抗GLP1R的单克隆抗体,可拮抗多个物种的GLP1R。
  • 体外实验显示Glp1R0017可减弱GLP-1刺激的cAMP和胰岛素分泌。
  • 体内实验表明Glp1R0017可逆转利拉鲁肽的降糖作用并降低糖耐量。

核心结论

  • Glp1R0017是一种结合胰腺β细胞GLP1R并在体内阻断GLP-1作用的单克隆拮抗抗体,有望用于研究GLP1R在胰腺外组织中的生理重要性。

研究设计与样本

  • 利用天然噬菌体展示选择策略分离结合GLP1R的单链可变区片段,将亲和力最高的Glp1R0017转换为人类IgG1并进行表征;体外通过cAMP均相时间分辨荧光 assay、活细胞cAMP成像和INS-1 832/3细胞胰岛素分泌实验评估拮抗活性;体内通过C57/Bl6小鼠的IPGTT和OGTT评估Glp1R0017阻断GLP1R的能力。

主要发现

  • Glp1R0017可拮抗小鼠、人、大鼠、食蟹猴和犬的GLP1R,且拮抗活性特异性针对GLP1R,对过表达GIPR、GLP-2R或胰高血糖素受体的细胞无拮抗活性。
  • 在INS-1 832/3细胞中,Glp1R0017孵育减弱了GLP-1刺激的cAMP和胰岛素分泌。
  • 小鼠胰腺组织免疫染色显示Glp1R0017在朗格汉斯岛特异性染色,而在Glp1r敲除组织中无染色。
  • 在IPGTT中,Glp1R0017逆转了利拉鲁肽的降糖作用;在OGTT中,通过阻断内源性GLP-1作用降低了糖耐量。

关键数值与推荐

  • Glp1R0017拮抗小鼠、人、大鼠、食蟹猴和犬的GLP1R。
  • 在INS-1 832/3细胞中,Glp1R0017减弱GLP-1刺激的cAMP和胰岛素分泌。
  • 在IPGTT中,Glp1R0017逆转利拉鲁肽的降糖作用;在OGTT中,降低糖耐量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Glucagon like peptide-1 (GLP-1) enhances glucose-dependent insulin secretion by binding to GLP-1 receptors (GLP1Rs) on pancreatic beta cells. GLP-1 mimetics are used in the clinic for the treatment of type 2 diabetes, but despite their therapeutic success, several clinical effects of GLP-1 remain unexplained at a mechanistic level, particularly in extrapancreatic tissues. The aim of this study was to generate and characterise a monoclonal antagonistic antibody for the GLP1R for use in vivo. METHODS: A naive phage display selection strategy was used to isolate single-chain variable fragments (ScFvs) that bound to GLP1R. The ScFv with the highest affinity, Glp1R0017, was converted into a human IgG1 and characterised further. In vitro antagonistic activity was assessed in a number of assays: a cAMP-based homogenous time-resolved fluorescence assay in GLP1R-overexpressing cell lines, a live cell cAMP imaging assay and an insulin secretion assay in INS-1 832/3 cells. Glp1R0017 was further tested in immunostaining of mouse pancreas, and the ability of Glp1R0017 to block GLP1R in vivo was assessed by both IPGTT and OGTT in C57/Bl6 mice. RESULTS: Antibodies to GLP1R were selected from naive antibody phage display libraries. The monoclonal antibody Glp1R0017 antagonised mouse, human, rat, cynomolgus monkey and dog GLP1R. This antagonistic activity was specific to GLP1R; no antagonistic activity was found in cells overexpressing the glucose-dependent insulinotropic peptide receptor (GIPR), glucagon like peptide-2 receptor or glucagon receptor. GLP-1-stimulated cAMP and insulin secretion was attenuated in INS-1 832/3 cells by Glp1R0017 incubation. Immunostaining of mouse pancreas tissue with Glp1R0017 showed specific staining in the islets of Langerhans, which was absent in Glp1r knockout tissue. In vivo, Glp1R0017 reversed the glucose-lowering effect of liraglutide during IPGTTs, and reduced glucose tolerance by blocking endogenous GLP-1 action in OGTTs. CONCLUSIONS/INTERPRETATION: Glp1R0017 is a monoclonal antagonistic antibody to the GLP1R that binds to GLP1R on pancreatic beta cells and blocks the actions of GLP-1 in vivo. This antibody holds the potential to be used in investigating the physiological importance of GLP1R signalling in extrapancreatic tissues where cellular targets and signalling pathways activated by GLP-1 are poorly understood.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Biggs EK, Liang L, Naylor J, et al. Development and characterisation of a novel glucagon like peptide-1 receptor antibody. Diabetologia. 2017. PMID: 29119245. doi:10.1007/s00125-017-4491-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。